Home > Boards > US Listed > Biotechs >

Regen BioPharma Inc. (RGBP)

Add RGBP Price Alert      Hide Sticky   Hide Intro
Moderator: gotinearly, ronrooster
Search This Board: 
Last Post: 3/22/2020 10:42:54 PM - Followers: 375 - Board type: Free - Posts Today: 0


Regen BioPharma 
Followers: 388 Since 10/10/19

 0.0008  Ticker Symbol: RGBP 
Last iBox update 10/21/19 4PM by CrazyKar123



Cell Therapy Technologies Market – Global Industry Insights and Forecast year 2018-2025
SAN DIEGO , Aug. 15, 2019 /PRNewswire/ -- Regen BioPharma Inc. (OTCQB: RGBP) and (OTCQB: RGBPP),
Regen BioPharma Inc. Files Immuno-Oncology Patent Application on Synergy of Cannabidiol With NR2F6 Modulation

All other Regen BioPharma News


Regen BioPharma, Inc. 4700 Spring Street, Suite 304
La Mesa, CA 91942 U.S.A.

Telephone: (619) 702-1404
Fax: (619) 330-2328

Regen BioPharma Inc. is a publicly traded biotechnology company (OTCQB: RGBP) and (OTCQB: RGBPP)  focused on the immunology and immunotherapy space. The Company plans to rapidly advance novel technologies through pre-clinical and Phase I/ II clinical trials. Currently, the Company is advancing small molecule therapies for treating cancer and autoimmune disorders by modulating the Checkpoint NR2F6.  The company also developing products treating blood disorders using small molecules and gene silencing (DiffronC), treating cancer with cellular immunotherapy (dCellVax), modulating key molecular processes in cancer stem cell through its patented molecular targeting approaches (BORIS), and repairing damaged bone marrow in patients with aplastic anemia and chemotherapy/radiotherapy treated cancer patients (HemaXellerate).


Product Pipeline | Regen BioPharma, Inc.

Small Molecules Targeting Cancer and Autoimmunity

Regen has identified and filed patents on small molecules that activate and inhibit a novel gene (NR2F6) which controls how the immune system reacts to cancer cells and to inflammatory responses.
  • Objective is to identify small molecules that can activate and inhibit NR2F6
    ?Currently in pre-clinical development 
    Initial indications (inhibitor): bladder cancer, myelodysplastic syndrome, lung cancer
    Initial indications (activator): rheumatoid arthritis, inflammatory bowel disease, psoriasis
    Additional indications include solid tumors, acute leukemia and GVHD


Aplastic Anemia Stem Cell Therapy – HemaXellerate – IND #15376 CLEARED TO PROCEED TO PHASE I / II CLINICAL TRIALS
HemaXellerate is a personalized cellular therapeutic product designed to stimulate blood production in patients whose bone marrow is not properly functioning.
  • Fat stem cell based product to treat bone marrow that has been damaged
    Bone marrow damage occurs from radiation, chemo, or chronic conditions
    HemaXellerate uses patient’s own fat as source of endothelial cells to heal damaged bone marrow 
    ?United States Food and Drug Administration Investigational New Drug Application cleared (IND #15376)



Breast Cancer – dCellVax - IND #16200
CellVax is a dendritic cell based immunotherapy that stimulates the patient’s immune system through a process called “gene silencing.”
  • 10 advanced breast cancer patients
    Efficacy endpoints at 6 and 12 months
    Establishment of safety will allow for rapid expansion of patient numbers 
    Currently addressing FDA questions with Dr. Santosh Kesari, head of UCSD Neuro-Oncology program 



Myelodysplastic Syndrome Gene Silencing – DiffronC
DiffronC is a novel form of therapy called differentiation therapy that is expected to have much milder toxicity than chemotherapy. The mechanism of action is to correct the specific genes that prevent the myelodysplastic syndrome stem cell from producing mature blood cells.
  • siRNA silencing of our newly discovered cancer stem cell target gene
    Silencing using DiffronC induces differentiation of cancer cells 
    Initial indication is treatment of myelodysplastic syndrome 
    Other indications include solid tumors and acute leukemia


Telomeres & Genomic Integrity

Stem cells and cancer cells have found ways of maintaining their telomeres in a state that prevents senescence. Our research in to the cancer stem cell has given us a molecular pathway that can be manipulated to expand stem cells and maintain telomeres.
  • Telomeres are protective structures at the ends of chromosomes that enable cell divisions
    Telomere attrition is involved in aging, cancer and genetic mutations 
    We are developing drugs that modulate telomere maintenance 
    In pre-clinical development for indications of solid cancers and acute leukemia

Image result for cbd


Regen BioPharma, Inc. Examines Combining Cannabidiol (CBD) With Its Lead NR2F6 Agonist To Treat for Inflammatory Bowel Disease


SAN DIEGO, January 8, 2019 /PRNewswire/ --   https://www.otcmarkets.com/stock/RGBP/news/Regen-BioPharma-Inc-Examines-Combining-Cannabidiol-CBD-With-Its-Lead-NR2F6-Agonist-To-Treat-for-Inflammatory-Bowel-Disea?id=214869

Regen BioPharma, Inc. (OTCQB: RGBP) and (OTCQB: RGBPP), reports its researchers have determined that combining its lead NR2F6 small molecule agonist with Cannabidiol (CBD) may provide a dynamic therapy for treating inflammatory bowel disease (IBD). Currently, there are a number of pre-clinical and clinical studies being conducted by other companies regarding pain management that suggest potential benefits of CBD. Regen believes that CBD may augment the Company's small molecule therapies for autoimmune disorders, in this case specifically IBD.

IBD is a disease caused by persistent and chronic inflammation of the gastrointestinal tract and is a term that refers to both ulcerative colitis and Crohn's disease. Current treatments include non-specific immune suppressors such as steroids as well as newer drugs recently approved by the FDA. The IBD market size is estimated at $6.7 billion global and projected to be $7.6 billion by 2023.There are currently no non-steroidal therapies  available to IBD sufferers.

"Our ex-vivo studies with RG-NAH005 (Regen's small molecule agonist) support moving the drug into animal studies where we can measure the effect of the drug on different diseases," says Harry Lander, Ph.D., President and Chief Scientific Officer of Regen.  "We believe incorporating CBD in our studies will allow us to potentially strengthen positive outcomes for patients."

The NR2F6 nuclear receptor has been identified as a potentially very important immune cell inhibitor (an immune checkpoint) and cancer stem cell differentiator. The NR2F6 small molecule program at Regen aims to identify antagonists of NR2F6 in an effort to unleash the cancer-killing potential of a patient's own immune system as well as identifying agonists which should suppress the immune system in diseases where the immune system is over-activated, such as autoimmunity and chronic inflammation.

"We are pleased that RG-NAH005 has shown a safety profile that allows us to move it into animal studies," says David Koos, Ph.D., Chairman & CEO of both Regen BioPharma, Inc. and Zander Therapeutics, Inc. "We are enthusiastic that combining CBD with our small molecule agonist will potentially make our small molecule therapy for IBD more dynamic is its approach to treating this disease."



Always research for yourself BEFORE you buy in the OTC !!!!

Current Price
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
#37215  Sticky Note UNITED STATES ronrooster 01/12/20 12:43:12 PM
#27909  Sticky Note ELI LILLY HAS RGBP SCREENING COMPOUNDS FOR THEM!!!!!!!!!!! gotinearly 06/30/16 09:23:49 AM
#37305   Yes, preferred shares will get preferential treatment when SanDiegoAlan 03/22/20 10:42:54 PM
#37304   I believe the preferred would receive preferential treatment ronrooster 03/20/20 01:35:22 PM
#37303   Someone was buying up the Preferred Shares yesterday. Due Diligence Virtuoso 03/20/20 12:27:53 PM
#37302   Not new, however just came accross this info ronrooster 03/08/20 11:46:19 AM
#37301   Did you see that Zander has an accepted ronrooster 03/05/20 12:38:20 PM
#37300   Maybe they were able to sell their convertible SanDiegoAlan 03/05/20 12:34:07 PM
#37299   Of note is the fact that Regen Has ronrooster 03/05/20 10:17:35 AM
#37298   The note holders are not identified on the SanDiegoAlan 03/04/20 02:20:53 PM
#37297   You may be correct although after reviewing the ronrooster 03/04/20 02:07:02 PM
#37296   LG Capital was a convertible note holder. They SanDiegoAlan 03/04/20 12:55:30 PM
#37295   Great News! Thanks Rooster! Time to move! rrao11 03/04/20 08:32:46 AM
#37294   13 G out REGEN PREFERRED SHARES.LG CAPITAL FUNDING, ronrooster 03/03/20 11:35:25 AM
#37293   It's all up to a judge or jury. SanDiegoAlan 02/26/20 02:50:27 AM
#37292   Thanks SanDiego. If Regen cannot pay the rrao11 02/25/20 03:50:06 AM
#37291   Regen will have to pay them 1.2 million SanDiegoAlan 02/25/20 02:46:50 AM
#37290   *chemdiv rrao11 02/22/20 03:22:19 PM
#37289   So, what happens to Regen if Chem doc wins? rrao11 02/22/20 12:57:40 PM
#37288   Yes, after Chemdiv wins the parents from their SanDiegoAlan 02/22/20 01:47:19 AM
#37287   Hopefully it won't be long now before RGBP's Halp 02/21/20 04:05:01 PM
#37286   Reading is fundamental. ADVFN_franknstein 02/19/20 01:58:24 PM
#37285   Got it lab40 02/19/20 11:14:25 AM
#37284   BMSND Kbro13 02/19/20 10:46:39 AM
#37283   BSMN board is gone? lab40 02/19/20 10:28:41 AM
#37281   Worth buying? Well the CEO just bailed, they've SanDiegoAlan 02/15/20 11:01:56 PM
#37280   Really worth buying? Chrism0000 02/15/20 03:44:31 PM
#37279   very interesting! gotinearly 02/15/20 09:25:15 AM
#37277   I doubt that there is any further dilution SanDiegoAlan 02/14/20 02:13:18 PM
#37276   Thanks Cents. GLTU2. rrao11 02/14/20 12:13:31 PM
#37275   i sent you a link centsability4me 02/14/20 12:08:49 PM
#37274   Thanks Cents. Answers from all are welcome, rrao11 02/14/20 11:59:53 AM
#37273   lol reading up on trips right now w/ I*RC centsability4me 02/14/20 11:34:17 AM
#37272   lol, bwhahaha gotinearly 02/14/20 11:32:28 AM
#37271   rrao11, SanDiegoAlan and SidVicious have been here longer centsability4me 02/14/20 11:16:06 AM
#37270   GM Cents - any idea if $RGBP is rrao11 02/14/20 09:56:55 AM
#37269   They never where...According to the PR Regen was gotinearly 02/13/20 03:59:03 PM
#37268   Sorry Foat is the name, he works out lab40 02/13/20 10:40:30 AM
#37267   There is no Craven, only Flat, who's been lab40 02/13/20 10:39:00 AM
#37266   so now that Koos is trying to be SidVicious 02/13/20 10:18:11 AM
#37265   Hey GIE, SidVicious 02/13/20 10:15:13 AM
#37261   Who is selling at 0.0001? rrao11 02/11/20 06:13:08 PM
#37260   This stock has nothing to do with Icham lab40 02/10/20 11:18:48 AM
#37258   everything to bash even say someone is dead... Italia77 02/09/20 06:56:08 AM
#37256   notice the spelling it used...total intentional sham gotinearly 02/08/20 09:46:21 AM
#37255   Even after finding out your "news" was incorrect, slb5150 02/07/20 11:04:43 PM
#37251   Unreal, what a flat out lie. gotinearly 02/06/20 05:09:19 PM
#37250   Wait, why would a friend misspell his name gotinearly 02/06/20 01:14:21 PM
#37247   it's a fake rumor centsability4me 02/06/20 08:19:37 AM
#37246   it's a fake rumor centsability4me 02/06/20 08:17:45 AM
#37245   This is false information about Thomas Icham. He Scotontheblock1 02/06/20 07:57:57 AM
#37244  Restored It’s terrible, you likely communicated with a family Ashstemcell 02/06/20 07:56:02 AM